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Objective: The aim of the study is to compare ultrasound-guided foam sclerotherapy (UGFS: injection of
foam sclerosant under ultrasound guidance) of the great saphenous vein (GSV) combined with visual
foam sclerotherapy (VFS: injection of foam sclerosant under visual control) for varicose tributary veins
and VFS alone in the treatment of GSV reﬂux.
Design and methods: A total of 133 limbs in 97 patients with GSV reﬂux were randomised to receive either
VFS alone or VFS combined with UGFS. In both groups, 1% polidocanol foam was used. Assessments
included duplex ultrasonography, evaluation of Venous Clinical Severity Scores (VCSS) and CEAP (clinical,
etiologic, anatomic, and pathophysiologic) scores. Ultrasonographic inspection of the foam in the GSV
was carried out during 5 min before compression was applied. The primary ‘end’ point of the study was
obliteration of the GSV at 6 months.
Results: A total of 51 limbs in 48 patients were treated with UGFS þ VFS and the remaining 52 limbs in 49
patients were treated with VFS alone. There were no signiﬁcant inter-group differences in patient age,
male: female ratio, height, weight, body mass index, CEAP clinical scores or VCSS. The GSV diameter was
6.0  1.7 mm (median  interquartile range) in the UGFS þ VFS group and 5.7  1.6 mm in the VFS group
(p ¼ 0.419). The mean injected volume of foam for varicose tributary veins was 4  2 ml in the
UGFS þ VFS group and 6  2 ml in the VFS group, a signiﬁcantly higher amount of foam being used in the
latter (p < 0.001). However, the mean total amount of foamwas greater in limbs treated with UFGS þ VFS
than in those treated with VFS alone (p ¼ 0.017). Ultrasonographic inspection revealed complete vaso-
spasm of the GSV in 37 (72.5%) limbs in the UGFS þ VFS group and 29 (55.8%) in the VFS group during
sclerotherapy (p ¼ 0.097). At 6-month follow-up, complete occlusion was found in 23 limbs (45.1%)
treated with UGFS þ VFS and in 22 limbs (42.3%) treated with VFS. The difference between the two
groups was not signiﬁcant (p ¼ 0.775). Reﬂux was absent in 30 limbs (58.8%) treated with UGFS þ VFS
and in 37 (71.2%) treated with VFS (p ¼ 0.190). There was no inter-group difference in post-treatment
VCSS (p ¼ 0.223).
Conclusions: These results show that UGFS þ VFS and VFS are equally effective for the treatment of GSV
reﬂux, despite the lower volume of foam used for VFS alone.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Over the last decade, ultrasound-guided foam sclerotherapy
(UGFS) has largely replaced liquid sclerotherapy in the treatment of
superﬁcial venous insufﬁciency.1e9 The use of liquid sclerosants has
the limitations of dilution, inactivation and irregular distribution of
the sclerosant on the endothelium. By contrast, foam sclerosants
displace the blood and concentrate their effect on the intima morethe American Venous Forum,
: þ81 3 3225 0940.
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ciety for Vascular Surgery. Publisheintensely than liquid sclerosants due to homogeneous distribution
of the sclerosant over the endothelial surface. This has facilitated
a reduction in both the volume and concentration of these agents
compared with liquid sclerotherapy.10,11 Thus, foam sclerotherapy
has become popular in the treatment of superﬁcial venous insuf-
ﬁciency, and the use of liquid polidocanol has now been reserved
for only spider, reticular and small varicose veins. Alternative
treatments include conventional surgery and endovenous laser or
radiofrequency ablation of the incompetent truncal veins.
In clinical practice, most patients receiving foam sclerotherapy
are managed with ultrasound-guided injection of foam into thed by Elsevier Ltd. All rights reserved.
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However, if excess foam is injected into the tributary veins, it often
travels to the GSV and can cause immediate and dramatic spasm
along the whole length of the vein. This prevents the effective use
of UGFS. To our knowledge, no previous reports have described the
effect of excessive foam migration on GSV vasospasm. The purpose
of the present study was to compare the effectiveness of visual
foam sclerotherapy (VFS) alone for varicose tributary veins with
that of VFS combined with UGFS in patients with primary varicose
veins associated with truncal vein incompetence.
Materials and Methods
Patients
The study subjects comprised 97 patients (31males: 66 females;
age 27e88 years (mean 68.8 years); 103 limbs) who were treated
for GSV reﬂux associated with sapheno-femoral junction (SFJ)
incompetence between January 2010 and July 2010. The patients
were prospectively randomised to receive either VFS alone or VFS
combined with UGFS of the GSV. Patients’ height, weight and body
mass index (BMI; kg m2) were also recorded as well as their CEAP
(clinical, etiologic, anatomic, and pathophysiologic) score.12 In this
study, all of the patients were classiﬁed as C2,3,4a,4b,Ep,As,Pr2,3. To
assess any improvement in symptoms in response to treatment, the
patients were assessed using the revised Venous Clinical Severity
Score (VCSS) before and 1, 3 and 6 months after foam scle-
rotherapy.13 Patients with myocardial ischaemia, arterial insufﬁ-
ciency with an ankleebrachial index of less than 0.9, in the ﬁrst
trimester of pregnancy and after the 36th week of gestation, local
infection in the area for sclerotherapy, active thrombophlebitis and
acute deep vein thrombosis were excluded from the study. The
study was approved by the institutional review board, and
informed consent was obtained from all participants.
Pre-treatment ultrasonographic evaluation
Pre-treatment examination was performed using a colour
duplex scanner (LOGIQ 7 PRO; GE Yokogawa Medical Systems,
Tokyo, Japan) with a 5e10-MHz transducer to detect venous reﬂux
at the SFJ and in the GSV. Venous reﬂux was assessed while the
patient was standing. For evaluation of the SFJ, a pneumatic thigh
cuff (Hokanson, Bellevue, WA, USA) was attached to the thigh,
inﬂated to 80 mmHg and then rapidly deﬂated. For evaluation of
the GSV, the transducer was placed 10 cm above knee level, and
a cuff was applied to the calf, inﬂated to 100 mmHg and then
rapidly deﬂated. The diameter (mm) of the GSV was measured in
cross-sectional view while the patient was standing. Venous reﬂux
was considered to be present if the reﬂux time (RT) exceeded 0.5 s.
Additional ultrasound-derived parameters assessed were peak
reﬂux velocity (PRV; cm s1), mean reﬂux velocity (MRV; cm s1)
and total reﬂux volume (TRV; ml) calculated using the equation:
TRV (ml) ¼ MRV  Area (r2)  RT. The vessel cross-sectional area
was estimated from the diameter, assuming a circular vessel shape.
Foam sclerotherapy
The sclerosant foamwas prepared by Tessari’s method using 1%
polidocanol (POL: Polidocasclerol, Zeria Pharmaceutical Co. Ltd.,
Tokyo, Japan).1 Because one of the purposes of this study was to
compare the success rates achieved in the two groups under the
same conditions, all patients received the same sclerosant andwere
allowed only one additional treatment session during the follow-up
period of 6 months. After detailed anatomical mapping with duplex
ultrasound, patients were placed supine with their affected leg(s)elevated 30. Each visible varicose tributary vein was injected ﬁrst
using 23-gauge butterﬂy needles. Patients who were treated with
UGFS combined with VFS received <0.5 ml POL foam per injection
to minimise any foam migration beyond the target vein.14 Subse-
quently 1% POL foam was injected into the GSV under ultrasound
guidance, starting 3e4 cm distal to the SFJ.15 A second injectionwas
performed 5e10 cm distal to the initial point using a 21-gauge
venous catheter. The GSV cannulae were inserted before injection
of the tributaries. Patients who were treated with VFS alone
received 0.6e1.0 ml POL foam per injection. Thus, the total amount
of injected foam did not exceed 10 ml in any of the cases.9 Ultra-
sonographic inspection of the foam was then performed for 5 min
after completion of foam sclerotherapy using duplex ultrasound
(DUS) in both longitudinal and transverse section to reduce arte-
facts produced by the foam. The ﬁndings on DUS were classiﬁed
into one of three groups:
(1) Complete vasospasm: The GSV showed complete vasospasm
throughout its length.
(2) Moderate vasospasm: A maximum reduction in GSV diameter
>50%.
(3) Poor vasospasm: Amaximum reduction in GSV diameter<50%.
If vasospasmwas complete distally but only >50% proximally, it
was graded as >50%.
After completion of the DUS examination, compression pads
and elastic bandages were applied, and kept on continuously for
the ﬁrst 2 days. All the patients were encouraged to ambulate after
the treatment. On post-sclerotherapy day 3, the elastic bandages
and compression pads were removed, and a class II thigh-high
compression stocking was applied.
Post-sclerotherapy follow-up
To evaluate the efﬁcacy of foam sclerotherapy, post-
sclerotherapy surveillance was done at 2 weeks, and 1, 3 and 6
months using DUS. The primary ‘end’ point of the study was
obliteration of the GSV at 6 months. The results of DUS were clas-
siﬁed as follows:
(1) complete occlusion: The GSV had shrunk and was occluded;
(2) partial GSV recanalisation with no reﬂux;
(3) partial GSV recanalisation with reﬂux; and
(4) complete GSV recanalisation with reﬂux.Statistical analysis
All data were analysed using the Statistical Package for Social
Science (SPSS) software package (Version 16.0; SPSS Inc., Chicago,
IL, USA). Comparisons of numerical data between groups of patients
were made using Student’s t test. Chi-squared contingency table
analysis was used to evaluate differences between proportions.
Continuous data were expressed as median  interquartile range.
Statistical signiﬁcance was deﬁned as p < 0.05.
Results
Patient characteristics
Table 1 summarises the baseline characteristics of the two study
groups. A total of 51 limbs in 48 patients were treated with
UGFS þ VFS, and 52 limbs in 49 patients were treated with VFS
alone. There were no inter-group differences in age (p ¼ 0.918) or
male: female ratio (p ¼ 0.406). Patients’ height, weight and BMI
Table 3
Ultrasonographic evaluation of GSV vasospasm 5 min after completion of foam
sclerotherapy.
UGFS þ VFS
n ¼ 51 limbs
VFS
n ¼ 52 limbs
p-value
Complete vasospasm (%) 37 (72.5) 29 (55.8) 0.097
Moderate vasospasm (%) 13 (25.5) 14 (26.9) 0.869
Poor vasospasm (%) 1 (2.0) 9 (17.3) 0.009
Complete vasospasm: the GSV showed complete vasospasm.
Moderate vasospasm: maximum reduction in GSV diameter of more than 50%.
Poor vasospasm: maximum reduction in GSV diameter of less than 50%.
Table 4
Outcome of foam sclerotherapy.
Ultrasonographic
inspection
UGFSþVFS
n ¼ 51 limbs
VFS
n ¼ 52 limbs
p-value
Complete occlusion (%) 23 (45.1) 22 (42.3) 0.775
Partial recanalisation
with no reﬂux (%)
7 (13.7) 15 (28.8) 0.061
Total 30 (58.8) 37 (71.1) 0.190
Table 1
Baseline characteristics grouped by use or non-use of ultrasound-guided foam
sclerotherapy.
UGFS þ VFS
n ¼ 48 patients
VFS
n ¼ 49 patients
p-value
Age (yr) 69  13 69  13 0.918
Female gender,
no (%)
36 (75.0) 33 (67.3) 0.406
Height (m) 1.58  0.91 1.58  1.45 0.381
Weight (kg) 55.0  11.1 56.5  12.0 0.903
BMI (kg/m2) 22.8  3.7 22.0  2.9 0.693
CEAP Clinical
classiﬁcation*
n ¼ 51 limbs n ¼ 52 limbs p-value
C2 (%) 39 (76.5) 36 (69.2) 0.409
C3 (%) 1 (1.9) 1 (1.9) 0.989
C4a (%) 8 (15.7) 13 (25.0) 0.241
C4b (%) 3 (5.9) 2 (3.9) 0.631
UGFS: ultrasound-guided foam sclerotherapy, VFS: visual foam sclerotherapy.
*CEAP Clinical classiﬁcation: C2, varicose veins; C3, oedema without skin changes;
C4a, pigmentation or eczema; C4b, lipodermatosclerosis or atrophie blanche.
VCSS: Venous Clinical Severity score.
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respectively). Finally, there was no inter-group difference for each
CEAP class in the two groups (p ¼ 0.409, 0.989, 0.241 and 0.631,
respectively), with the majority (UGFS þ VFS: 77%; VFS: 69%)
having uncomplicated varicose veins (CEAP C2). Successful cannula
placement and ultrasound-monitored foam injection were
accomplished in all patients without any immediate complications.
Ultrasound-derived haemodynamic variables before foam
sclerotherapy
Table 2 shows the pre-treatment ultrasound-derived haemo-
dynamic variables in the two groups. The mean GSV diameter was
6.0mm in the UGFSþVFS group and 5.7mm in the VFS alone group
(p ¼ 0.419). Similarly, there was no signiﬁcant inter-group differ-
ence in the RT (p ¼ 0.142), or in PRV, MRV or TRV (p ¼ 0.757, 0.772
and 0.571, respectively).
Volume of sclerosing foam
The mean injected volume of foam for varicose tributary veins
was 4  2 ml in the UGFS þ VFS group and 6  2 ml in the VFS
group, a signiﬁcantly higher amount of foam being used in the
latter (p < 0.001). However, the mean total amount of foam was
greater in limbs treated with UFGSþ VFS than in those treated with
VFS alone (p ¼ 0.017).
Ultrasonographic inspection of sclerosant foam
Table 3 shows the degree of vasospasm in each group 5min after
the completion of foam sclerotherapy. There was no difference
between them in respect of either complete or moderate GSVTable 2
Comparison of ultrasound-derived haemodynamic variables before foam
sclerotherapy.
Ultrasonographic evaluation UGFS þ VFS
n ¼ 51 limbs
VFS
n ¼ 52 limbs
p-value
Diameter (mm) 6.0  1.7 5.7  1.6 0.419
Reﬂux times (s) 4.5  4.1 5.3  4.4 0.142
Peak reﬂux velocity (cm/s) 48.4  26.0 49.8  29.2 0.757
Mean reﬂux velocity (cm/s) 18.2  13.1 18.0  12.3 0.772
Total reﬂux volume (mL) 30.8  32.3 48.9  49.7 0.571
UGFS: ultrasound-guided foam sclerotherapy, VFS: visual foam sclerotherapy.vasospasm (p ¼ 0.097 and 0.869, respectively), although a higher
proportion of patients who received VFS alone had poor vasospasm
in comparison with the UGFS þ VFS group (p ¼ 0.009).Outcome of foam sclerotherapy
The outcomes for foam sclerotherapy are shown in Table 4. At 6-
month follow-up, there was no difference in the proportion of
patients with complete GSV occlusion (UGFS þ VFS 45.1%; VFS
42.3%: p ¼ 0.775) or elimination of GSV reﬂux (UGFS þ VFS 58.8%;
VFS 71.1%: p ¼ 0.190). Similarly, the proportion of patients showing
partial recanalisation with reﬂux (p ¼ 0.465), complete recanali-
sation (p ¼ 0.282) or recurrent varicose veins was no different
(p ¼ 0.485). Post-sclerotherapy GSV diameters were reduced in
both groups despite continuing reﬂux (p ¼ 0.788) and there was no
inter-group difference in the RT (p ¼ 0.836), or in PRV, MRV or TRV
(p ¼ 0.596, 0.351 and 0.579, respectively) in patients with reﬂux.
Table 5 shows the relationship between vasospasm during
sclerotherapy and elimination of reﬂux at 6months. The proportion
of limbs showing complete vasospasm and no reﬂuxwas greater for
UGFS þ VFS than for VFS alone, but the difference was not signiﬁ-
cant (p ¼ 0.159). Similarly, there was no signiﬁcant inter-group
difference in the proportion of limbs showing moderate vaso-
spasm with elimination of reﬂux (p ¼ 0.974). By contrast, a higher
proportion of limbs treated with VFS alone had poor vasospasm in
comparison with those treated with UGFS þ VFS (p ¼ 0.021),
despite elimination of reﬂux.
Table 6 shows the changes in the VCSS score in the two treat-
ment groups. There were no signiﬁcant inter-group differences in
either pre-treatment (p ¼ 0.706), or post-treatment VCSS at 6
months (p ¼ 0.223).Partial recanalisation
with reﬂux (%)
15 (29.4) 12 (23.1) 0.465
Complete
recanalisation (%)
6 (11.8) 3 (5.8) 0.281
Recurrent
varicose veins (%)
6 (11.8) 4 (7.8) 0.485
Post-sclerotherapy
reﬂux parameters
UGFSþVFS
n ¼ 21 limbs
VFS
n ¼ 15 limbs
p-value
Diameter (mm) 3.9  1.6 4.3  1.6 0.788
Reﬂux time (s) 2.2  2.3 2.5  1.8 0.836
Peak reﬂux velocity (cm/s) 17.2  17.0 18.7  29.2 0.596
Mean reﬂux velocity (cm/s) 8.1  8.2 8.8  10.3 0.351
Total reﬂux volume (mL) 2.8  3.5 3.0  3.8 0.579
Table 5
Relationship between degree of vasospasm 5 minutes after sclerotherapy and
elimination of reﬂux at 6-month follow-up.
UGFSþVFS
n ¼ 30 limbs
VFS
n ¼ 37 limbs
p-value
Complete vasospasm (%) 22 (73.3) 21 (56.8) 0.159
Moderate vasospasm (%) 8 (26.7) 10 (27.0) 0.974
Poor vasospasm (%) 0 (0) 6 (16.2) 0.021
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not serious. Superﬁcial thrombophlebitis occurred in one patient in
each of the groups and one patient treated with VFS experienced
migraine. No other serious complications occurred.
Discussion
This study investigated the efﬁcacy of VFS alone in comparison
with VFS combined with UGFS for treatment of GSV reﬂux. We
found that the volume of foam used was greater for UFGS þ VFS
than for VFS alone, but that elimination of reﬂux and the
improvement in VCSS score were no different.
The safety and efﬁcacy of UGFS as a minimally invasive treat-
ment for varicose veins have become widely accepted, and
a number of large case series have been reported.3e8 The use of an
appropriate concentration and volume of foam sclerosant yields
good short-term GSV occlusion rates. At the 2nd European
Consensus Meeting on Foam Sclerotherapy (ECMFS), most experts
reported using 3% POL to prepare foam for the treatment of GSV
reﬂux.9 However, recent studies comparing 1% and 3% POL foam
found that the two concentrations were equally effective when the
GSV trunk was <8 mm in diameter.16,17 Nevertheless Ceulen et al.
suggested that there was a clinically relevant, but non-signiﬁcant,
difference in the proportion with GSV occlusion between 1% and
3% POL foam (69.5% vs. 80.1%).18 The volume of foam injected may
also inﬂuence outcome. At the 2nd ECMFS, it was recommended
that no more than 10 ml of foam should be injected in a single
session. In reality, much less is usually required.16
To judge whether sufﬁcient foam has been delivered into the
GSV (vasospasm, conﬁrmation that foam ﬁlled the vein) DUS
inspection is mandatory.14,16 This approach can minimise the
volume of foam required during sclerotherapy. However, the
occurrence of vasospasm in the injected vein is considered merely
to indicate that the initial foam injection was satisfactory and re-
opening of the vein may occur despite the occurrence of vaso-
spasm.16 In the present study, we found that only 73% of the limbs
treated with UGFS þ VFS and 53% of those given VFS and showing
complete vasospasm had elimination of reﬂux at 6 months.
Conversely, in 16% of limbs treated with VFS and showing poor
vasospasm reﬂux was subsequently abolished. Thus, vasospasm is
not a reliable predictor of efﬁcacy.
Adverse events do not seem to occur as often if a limited volume
of foam is used in large varicose veins. Deep vein thrombosis has
been reported as a signiﬁcant complication of foam sclerotherapyTable 6
Changes in VCSS score after treatment in each of the two groups.
VCSS UGFS þ VFS
n ¼ 51 limbs
VFS
n ¼ 52 limbs
p-value
Pre-treatment 5  2 6  2 0.706
Post-treatment
1 mo 3  2 3  1 0.123
3 mo 2  1 2  1 0.198
6 mo 1  2 1  2 0.223only when a large amount of foam is used.19 Myers and associates
reported nine cases of occlusive posterior tibial vein thrombosis
and seven cases of partially occlusive femoro-poplitaeal thrombosis
with the use of 5e35 ml (median 14 ml) of foam, representing 1.8%
and 1.4% of the 489 studied patients, respectively.7
Stroke has also been reported in association with UGFS for GSV
incompetence after administering 20 ml of POL foam prepared by
the Tessari method.20 Theoretically, an air embolism can be fatal if
a volume of >1 ml kg1 is administered to the venous system.21 At
lower foam doses, the total gas load within the bubbles is better
solubilised, and the bubbles may become better separated spatially,
thus reducing coalescence.22 However, another report has stated
that there is no evidence for an increased risk of embolism resulting
from larger foam volumes in UGFS.7
To reduce the risk of large amounts of foam migrating to the
right heart, with the potential for embolisation to the central
nervous system, Hill et al. have reported an injection technique in
which the leg is elevated without occlusive pressure at the SFJ
when performing UGFS.23 Initial treatment of GSV reﬂux and
delayed sclerotherapy of the varicose tributaries may also reduce
the rate of foam migration. Finally, our previous study demon-
strated that the multiple small-dose injection (<0.5 ml per injec-
tion) technique can reduce foam migration into the deep venous
system during sclerotherapy.14
To our knowledge, no previous reports have documented
a positive effect of foam injected via incompetent tributary veins on
damage to the GSV beyond the target vein. Although the correlation
between vasospasm during UGFS and clinical outcome is conten-
tious,4,9 the present study conﬁrmed that foam injected into the
tributaries promoted GSV vasospasm in some patients. This
suggests that foam remained in the superﬁcial venous system and
DUS may not be required unless the clinician wishes to document
GSV spasm and ensure no passage of foam into the deep venous
system.
Our study had some potential limitations. In particular, the 6-
month follow-up period was too short to allow full evaluation of
the efﬁcacy of foam sclerotherapy. In addition, the limited sample
size could have introduced a type II statistical error. Finally, the
volume of foam employed was much smaller than that recom-
mended at the 2nd ECMFS, resulting in a relatively higher
proportion of patients showing poor vasospasm in the VFS alone
group. UGFS was performed for the proximal GSV alone and
a better outcome may have been obtained if the distal saphenous
trunk had been treated simultaneously.24
In conclusion, this present ﬁndings indicate that UGFS þ VFS
and VFS alone have equivalent efﬁcacy in the treatment of GSV
reﬂux, despite the lower volume of foam used for VFS alone.
Further studies are required to deﬁne the predictive factors for
successful outcome, especially in patients with uncomplicated
varicose veins, including factors such as vein diameter, foam
production techniques, the optimal volume of foam, the use of
physiologic gases, injection techniques and the optimal period of
use of compression stockings.Role of Funding Source
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